What is the safety and efficacy of Gamma-oryzanol (Oryxanol) for treating insomnia and anxiety in post-menopausal women?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Gamma-Oryzanol Should Not Be Recommended for Sleep and Anxiety in Postmenopausal Women

There is insufficient evidence to support the use of gamma-oryzanol (oryxanol) as a standalone treatment for insomnia and anxiety in postmenopausal women, and established guideline-recommended therapies should be prioritized instead.

Evidence-Based Treatment Hierarchy

For Insomnia in Postmenopausal Women

The American College of Physicians guideline explicitly states there is insufficient evidence to determine the safety or efficacy of complementary and alternative treatments for insomnia disorder 1. Instead:

  • Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia disorder in all adults, including postmenopausal women (strong recommendation, moderate-quality evidence) 1
  • CBT-I can be delivered through multiple modalities: individual therapy, group sessions, telephone/web-based modules, or self-help materials 1
  • Pharmacologic treatments should only be considered after CBT-I, with FDA warnings about cognitive/behavioral changes, driving impairment, and recommendations for lower doses in women and older adults 1

For Anxiety in Postmenopausal Women

While the Endocrine Society guideline addresses menopausal symptoms, it focuses on vasomotor symptoms and genitourinary syndrome, recommending SSRIs/SNRIs, gabapentin, or pregabalin for moderate-to-severe symptoms when hormone therapy is contraindicated 2. Anxiety as a primary symptom is not addressed with gamma-oryzanol in established guidelines.

Critical Analysis of Gamma-Oryzanol Evidence

FDA Drug Label Concerns

The FDA labeling for "Oryxanol" indicates it is approved for external use only 3, with dosing instructions for topical application 3. This directly contradicts oral use for systemic conditions like insomnia and anxiety, raising serious safety and regulatory concerns.

Research Evidence Limitations

While recent studies suggest potential benefits:

  • Two 2024-2025 Chinese studies showed gamma-oryzanol combined with Femoston (hormone therapy) improved sleep quality and anxiety symptoms in perimenopausal women 4, 5
  • However, gamma-oryzanol was never tested alone—it was always combined with hormone therapy, making it impossible to determine its independent efficacy
  • A 2019 mouse study showed anxiolytic effects through monoamine modulation 6, but animal data cannot be extrapolated to clinical recommendations
  • A 1982 Japanese study showed improvement in climacteric symptoms 7, but this predates modern evidence standards and lacks rigorous methodology

Safety Profile

  • Recent reviews note gamma-oryzanol has a "favorable safety profile" with minimal adverse effects in metabolic syndrome studies 8
  • However, a 2026 review on herbal supplements warns of risks including herb-drug interactions, adulteration, and lack of quality control 9
  • No long-term safety data exist specifically for postmenopausal women using gamma-oryzanol for neuropsychiatric symptoms

Clinical Pitfalls to Avoid

  1. Regulatory confusion: The FDA-approved topical formulation should not be confused with oral supplements marketed for systemic effects
  2. Combination therapy misinterpretation: Studies showing benefit used gamma-oryzanol with hormone therapy—the hormone therapy likely drove the clinical improvement
  3. Delaying effective treatment: Using unproven supplements delays access to evidence-based therapies (CBT-I for insomnia, SSRIs/SNRIs for anxiety)
  4. Quality control issues: Supplement formulations vary widely in purity and dosing, with risk of contamination or adulteration 9

Recommended Clinical Approach

For postmenopausal women presenting with insomnia:

  • Initiate CBT-I as first-line therapy 1
  • If CBT-I fails or is unavailable, consider FDA-approved hypnotics at reduced doses for women
  • Screen for and address underlying causes (sleep apnea, restless legs, depression)

For postmenopausal women presenting with anxiety:

  • Evaluate whether anxiety is related to vasomotor symptoms—if so, consider SSRIs/SNRIs or gabapentin/pregabalin per Endocrine Society guidelines 2
  • If primary anxiety disorder, refer for psychiatric evaluation and evidence-based treatment (psychotherapy, SSRIs/SNRIs)
  • Address hormone therapy candidacy if vasomotor symptoms are prominent

Regarding gamma-oryzanol specifically:

  • Cannot be recommended based on current evidence
  • If patients are already using it, counsel about lack of evidence, potential for adulteration, and importance of pursuing proven therapies
  • Monitor for herb-drug interactions if used alongside conventional medications

References

2
Guideline

treatment of symptoms of the menopause: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2015

Related Questions

Is it safe to take a supplement containing butterfly pea flower, chamomile, cinnamon, sweet blackberry leaves, red clover tops, natural vanilla flavor, blueberry fiber, lavender, and nutmeg together with desvenlafaxine and buspirone?
What anti‑inflammatory plant‑based supplements and succinate‑based supplements are recommended for a perimenopausal woman seeking non‑hormonal options for anxiety and insomnia?
Among sertraline, vitamin C, vitamin B12, magnesium, loperamide (Imodium), omeprazole, L‑theanine, melatonin, and chamomile, which agents could be causing peripheral edema?
What over-the-counter supplements are recommended for treating anxiety?
For a woman with daytime anxiety and insomnia on an SSRI (escitalopram or sertraline) who wants to avoid weight gain, what over‑the‑counter supplements such as ashwagandha, L‑theanine, and myo‑inositol can be recommended?
Why are some elderly patients prescribed vitamin D on an every‑other‑day schedule?
What is the simplest method to screen for bipolar disorder in a patient being treated for depression?
For what other conditions besides pancreatic cancer is carbohydrate antigen 19-9 (CA 19-9) used?
How should a 12-year-old female with persistent dizziness after a motor vehicle collision a few months ago be evaluated and managed?
Is laser hair removal covered by the Non‑Insured Health Benefits (NIHB) program when used for a recurrent pilonidal sinus that is causing infection?
What are the layers of the brain?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.